Table 2.
Anthropometric, clinical, and laboratorial profile in healthy subjects (controls) and in patients with rheumatoid arthritis (RA) with or without insulin resistance (IR).
| Controls (n = 97) | RA+ IR− (n = 91) | RA+ IR+ (n = 82) | Control versus RA+ IR− | Control versus RA+ IR+ | RA+ IR− versus RA+ IR+ | |
|---|---|---|---|---|---|---|
| Gender (F/M) | 80/17 | 70/21 | 70/12 | NS | NS | NS |
| Caucasian/not Caucasian | 72/25 | 58/33 | 53/29 | NS | NS | NS |
| Age (years) | 51.0 (42.5–69.5) | 56.0 (46.0–63.3) | 57.5 (48.8–62.3) | NS | NS | NS |
| BMI (kg/m2) | 25.8 (23.8–28.0) | 25.9 (22.8–29.3) | 29.4 (25.3–33.4) | NS | <0.0001 | <0.0001 |
| WC (cm) | 91.5 (87.0–97.3) | 90.0 (82.0–97.3) | 98.0 (91.0–107.3) | NS | <0.01 | <0.0001 |
| Glucose (mg/dL) | 87.0 (82.8–95.0) | 85.0 (80.0–90.0) | 96.0 (88.9–113.0) | NS | <0.0001 | <0.0001 |
| Insulin (μU/mL) | 6.35 (4.60–8.03) | 6.70 (5.30–8.10) | 13.95 (11.10–16.78) | NS | <0.0001 | <0.0001 |
| HOMA-IR | 1.35 (1.01–1.69) | 1.42 (1.07–1.75) | 3.41 (2.71–4.46) | NS | <0.0001 | <0.0001 |
| CL-LOOH (cpm) | 166.7 (141.9–179.0) | 169.2 (150.0–198.9) | 166.2 (152.6–201.5) | NS | NS | NS |
| AOPP (μmol/L of chloramines-T equivalents) | 150.4 (118.4–209.6) | 123.5 (100.4–171.3) | 173.8 (123.9–238.7) | <0.05 | NS | <0.0001 |
| TRAP (μM Trolox/mg UA) | 158.9 (122.2–200.9) | 171.5 (146.1–207.9) | 155.9 (121.0–177.3) | NS | NS | <0.05 |
| OSI | 0.228 (0.166–0.321) | 0.762 (0.578–0.952) | 1.183 (0.753–1.680) | <0.0001 | <0.0001 | <0.001 |
Kruskal-Wallis test with Dunn's posttest. Data are expressed as median (25–75%). BMI, body mass index; WC, waist circumference; HOMA-IR, homeostasis model assessment-insulin resistance; CL-LOOH, tert-butyl hydroperoxide-initiated chemiluminescence; AOPPs, advanced oxidation protein products; TRAP, total radical-trapping antioxidant parameter; and OSI, oxidative stress index.
NS: not significant.